Cell Therapies Market Overview
The T-cell therapy market is estimated to be worth $3.5 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 23% during the forecast period. Cancer is known to be one of the leading causes of deaths worldwide. In fact, as per the WHO, close to 10 million cancer related deaths were reported in 2020. Further, it is estimated that, by the end of 2040, 27.5 million new cancer cases will be added to the global numbers, exerting tremendous physical, emotional and financial strain on affected individuals, their families, communities and national health systems. Although there are several treatment options available to control disease progression and keep malignant cells from spreading throughout the body, lasting remission is difficult to achieve. In this context, immunotherapies, a relatively recent addition to the gamut of anticancer interventions, have demonstrated significant promise. Amidst the current initiatives undertaken to develop more targeted anti-cancer therapies, T-cell therapies (specifically CAR-T therapies, TCR therapies and TIL therapies) have emerged as a promising option, owing to their ability to eradicate tumor cells from the body with minimal treatment-related side effects. Overall, this highly specific and promising form of T-cell therapy treatment, which harnesses the versatile effector machinery of the human immune system, has revolutionized cancer treatment, globally. Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry. A number of chimeric antigen receptor T-cell (CAR-T) therapies have so far been evaluated and approved for several hematological malignancies, including KYMRIAH® (Novartis), YESCARTA® (Gilead Sciences), TECARTUS™ (Gilead Sciences), Breyanzi® (Bristol Myers Squibb), Abecma™ (Bristol Myers Squibb) and CARVYKTI™ (Janssen Biotech / Legend Biotech). It is worth mentioning that, recently, KIMMTRAK® (Immunocore) became the first T-cell receptor (TCR) therapy to receive approval from the USFDA.
Presently, more than 250 companies are engaged in the development of more than 1,200 early and late-stage T-cell therapies, worldwide. Several promising leads are anticipated to be commercially launched over the coming decade, following which the market is projected to grow at a substantial pace. Over 6,800 patents related to CAR-T therapies, TCR therapies and TIL therapies have been recently filed / granted, demonstrating the continued innovation in this domain. In addition, close to 440 collaborations have been inked between industry / academic stakeholders to advance the development of various pipeline candidates. Moreover, to fund product development initiatives in this domain, capital investments worth USD 30 billion have been made by various private and public sector investors in the last few years. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the T-cell immunotherapy market is anticipated to witness substantial growth in the mid to long-term.
Key Companies in T-Cell Therapy Market
Examples of key companies engaged in T-cell therapy market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Adaptimmune Therapeutics, Alaunos Therapeutics, Autolus, bluebird Bio, Bristol Myers Squibb, Carsgen Therapeutics, Cellectis, Cellular Biomedicine Group, Gilead Sciences and GlaxoSmithKline. This market report includes an easily searchable excel database of all the companies providing T cell therapies, worldwide.
Recent Developments in Cell Therapy Market:
Several recent developments have taken place in the field of cell therapy. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
- In August 2023, NKGen Biotech announced the dosing of SNK02, an lllogeneic NK cell therapy, to the first patient in Phase I clinical trial for the treatment of solid tumors.
- In August 2023, the FDA granted orphan drug designation (ODD) to NXC-201 (Nexcella), a next generation chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients suffering from multiple myeloma.
- In August 2023, GenScript Biotech entered into a strategic agreement with T-MAXIMUM Biotech with an aim to develop CAR-T cell therapy by using GenScript's CRISPR nucleic acid reagents.
Scope of the Report
The Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (6th Edition) - Distribution by Type of Therapy (CAR-T, TCR and TIL), Target Indications (Acute Lymphoblastic Leukemia, Non-Hodgkin’s Lymphoma, Melanoma, Bladder Cancer, Lung Cancer, Head and Neck Cancer, Multiple Myeloma, Sarcoma, Chronic Lymphocytic Leukemia, Ovarian Cancer, Esophageal Cancer, Colorectal Cancer, Nasopharyngeal Carcinoma, Hepatocellular Carcinoma, Acute Myeloid Leukemia and Renal Cell Carcinoma), Target Antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Global Forecast 2022-2035 report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. The report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the biopharmaceutical industry. The table below highlights various market segmentations done in the report.
2022 – 2035
Type of Therapy
|CAR-T therapy, TCR therapy, TIL therapy
|ALL, bladder cancer, cervical carcinoma, CLL, head and neck cancer, lung cancer, melanoma, multiple myeloma, NHL, ovarian cancer, sarcoma, others
|CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC2
|Altor Bioscience, Novartis, GlaxoSmithKline / Adaptimmune Therapeutics / Merck, Juno Therapeutics / Celgene / WuXi AppTec, Gilead Sciences
Key Geographical Regions
|North America, Europe, Asia-Pacific, MENA, Latin America, Rest of the World
|Key Geographical Regions
||North America (US and Canada), Europe (UK, France, Germany, Spain, Italy, Rest of EU) and Asia-Pacific (Japan and Australia)
|Key Companies Profiled
||Software, Elabscience, Goldsite Diagnostics, Hangzhou Testsea Biotechnology, Jiangsu Bioperfectus Technologies, Lansion Biotechnology, Bavarian Nordic and Emergent BioSolutions
||15% Free Customization Option
|PowerPoint Presentation (Complimentary)
|Excel Data Packs (Complimentary)
||Market Landscape Analysis, Product Competitiveness Analysis, Partnership and Collaboration Analysis, Grant Analysis, Publication Analysis, Porter's Five Forces Analysis, Market Forecast an Opportunity Analysis
Amongst other elements, the report features the following:
- A detailed assessment of the current market landscape of T-cell immunotherapies with respect to type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD22, CD20, Meso, CD7, HER2, GPC3, GD2, CD123, MUC, EGFR and CD38), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR-T cell therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific).
- An analysis of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
- A detailed analysis of completed, ongoing and planned clinical studies related to CAR-Ts, TCRs and TIL, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
- An insightful analysis highlighting the key opinion leaders (KOLs) in this domain featuring an analysis of the various principal investigators of clinical trials related to CAR-Ts, TCRs and TILs, considering them to be KOLs, who are actively involved in R&D of T-cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
- Elaborate profiles of marketed and mid- to late stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.
- A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of T-cell therapies), based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.
- An analysis of various type of partnership that have been inked between several stakeholders in the domain of T-cell therapies, covering various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
- An analysis of the investments that have been made into companies that have proprietary T-cell based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
- An in-depth analysis of patents related to CAR-Ts, TCRs and TILs, filed / granted till 2022, based on several relevant parameters, such as type of patent, publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
- A case study on other T-cell based therapies, apart from CAR-Ts, TCRs and TILs, including a detailed analysis of approved / pipeline products, featuring information on current phase of development, target therapeutic area(s), type of T-cells used and source of T-cells.
- A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
- An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a T-cell based immunotherapy that is likely to be marketed in the coming years.
- A review of the key promotional strategies being adopted by the developers of the approved CAR-T cell therapies, namely Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™ and TCR-based therapies (Kimmtrak®).
- Elaborate profiles of the several leading players in the domain of T-cell immunotherapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T, TCR and TIL therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for T-cell immunotherapies over the coming decade. Based on several relevant parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of T-cell immunotherapies that have been already commercialized or are in the late stages of development. Additionally, it features market size projections for the overall T-cell immunotherapies market, wherein both the current and upcoming opportunity is segmented across [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), [D] key players and [E] key geographies (North America, Europe, Asia Pacific, Latin America, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.
The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:
- Tim Oldham (Former Chief Executive Officer, Cell Therapies)
- Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
- Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
- Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
- Miguel Forte (Chief Operating Officer, TxCell)
- Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
- Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
- Peter Ho (Former Director, Process Development, Iovance Biotherapeutics)
- Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
- Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
- Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
- Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Frequently Asked Questions
Question 1: What is T cell therapy? Answer:
T cell therapy is a variation of immunotherapy which enables body’s own immune cells to identify and attack cancer cells, potentially treating a myriad of oncological conditions.
Question 2: How big is the T cell therapy market? Answer:
The T cell therapy market size is estimated to be worth $3.5 billion in 2023.
Question 3: What is the projected market growth of the T-cell therapy market? Answer:
The T-cell therapy market is expected to grow at compounded annual growth rate (CAGR) of 23% during the forecast period 2022 - 2035.
Question 4: What companies are involved in T cell therapy? Answer:
Examples of key companies engaged in T-cell therapy market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Adaptimmune Therapeutics, Alaunos Therapeutics, Autolus, bluebird Bio, Bristol Myers Squibb, Carsgen Therapeutics, Cellectis, Cellular Biomedicine Group, Gilead Sciences and GlaxoSmithKline.
Question 5: How many companies presently claim to develop novel T cell therapy? Answer:
Presently, over 250 companies are engaged in the development of more than 1,200 early and late-stage T cell therapies, worldwide
Question 6: Which region is expected to capture the majority of the market share in the T-cell therapy market? Answer:
North America presently captures over 30% market share of the T-cell therapy market, followed by Europe.
Question 7: Which type of indication is primarily targeted by companies engaged in the T-cell therapy market? Answer:
Majority of the T-cell therapy companies are focused on development of therapies for acute lymphoblastic leukemia.